• Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 501.50%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.33
▲ +0.03 (2.31%)

This chart shows the closing price for SCLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scilex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCLX

Analyst Price Target is $8.00
▲ +501.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Scilex in the last 3 months. The average price target is $8.00, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 501.50% upside from the last price of $1.33.

This chart shows the closing price for SCLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Scilex. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
10/13/2023B. RileyInitiated CoverageBuy$4.00Low
10/9/2023HC WainwrightInitiated CoverageBuy$12.00Low
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/16/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/15/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Scilex logo
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $1.33
Low: $1.28
High: $1.34

50 Day Range

MA: $1.57
Low: $1.30
High: $2.42

52 Week Range

Now: $1.33
Low: $0.90
High: $16.20

Volume

715,340 shs

Average Volume

823,448 shs

Market Capitalization

$221.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Scilex?

The following sell-side analysts have issued research reports on Scilex in the last year: B. Riley, and HC Wainwright.
View the latest analyst ratings for SCLX.

What is the current price target for Scilex?

2 Wall Street analysts have set twelve-month price targets for Scilex in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 501.5%. HC Wainwright has the highest price target set, predicting SCLX will reach $12.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $4.00 for Scilex in the next year.
View the latest price targets for SCLX.

What is the current consensus analyst rating for Scilex?

Scilex currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCLX will outperform the market and that investors should add to their positions of Scilex.
View the latest ratings for SCLX.

What other companies compete with Scilex?

How do I contact Scilex's investor relations team?

Scilex's physical mailing address is 1 Harbourfront Avenue #16-06 Keppel Bay Tower, Singapore U0, 098632. The company's listed phone number is 650-516-4310. The official website for Scilex is www.scilexholding.com. Learn More about contacing Scilex investor relations.